[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

Pfizer to buy RSV drug developer ReViral for up to $525 million

04/07/2022

Less than a minute

2022.04.07 14:07

Pfizer to buy RSV drug developer ReViral for up to $525 million
FILE PHOTO: A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. REUTERS/Dado Ruvic

(Reuters) – Pfizer Inc (NYSE:PFE) said on Thursday it would buy privately-held ReViral Ltd in a deal worth as much as $525 million, including milestone payments, to gain access to experimental drugs against the respiratory syncytial virus.

Source

04/07/2022

Less than a minute